# AHOD2131 (COG / NCTN)

Source: https://onco.cc/trials/ahod2131/  
OnCo record `ahod2131` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Asks whether early-stage Hodgkin lymphoma in children and adults can be treated with immunotherapy instead of some chemotherapy and radiation.

## Summary

AHOD2131, trial NCT05675410 run by the Children's Oncology Group and the NCI, asks whether early-stage classical Hodgkin lymphoma in children and adults aged 5 to 60 can be treated with brentuximab vedotin plus nivolumab in a response-adapted design, instead of some chemotherapy and radiation. It uses PET after two cycles to steer therapy, has progression-free survival as its primary endpoint, measures late effects, and is ongoing with no results yet. OnCo links it to Hodgkin lymphoma, PET-adapted therapy, brentuximab vedotin, nivolumab, the Children's Oncology Group, Kara M. Kelly, the idea of chemotherapy-free early-stage Hodgkin treatment and the S1826 paper. Whether immunotherapy can spare young patients the late effects of chemotherapy and radiation without losing cures is the question it exists to answer.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-07
- Registry id: NCT05675410
- Phase: 3
- Setting: Newly diagnosed stage I-II classical Hodgkin lymphoma, age 5-60: standard therapy vs brentuximab vedotin + nivolumab (response-adapted), with or without radiation
- Sponsor: Children's Oncology Group / NCI

## Sources

- ClinicalTrials.gov NCT05675410: https://clinicaltrials.gov/study/NCT05675410

## Connected records

- cancers: [Early-stage classical Hodgkin lymphoma (stage I to II)](https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- technologies: [PET-adapted (response-adapted) therapy](https://onco.cc/technologies/pet-adapted-therapy/)
- drugs: [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Fludeoxyglucose F-18 (FDG)](https://onco.cc/drugs/fludeoxyglucose-f18/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Children's Oncology Group (COG)](https://onco.cc/companies/childrens-oncology-group/)
- people: [Kara M. Kelly](https://onco.cc/people/kara-kelly/)
- ideas: [Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage](https://onco.cc/ideas/idea-chemo-free-hodgkin/)
- key papers: [SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults](https://onco.cc/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/ahod2131.json